These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 7641593

  • 21. [Second neoplasms as a late complication of the treatment of Hodgkin's disease].
    Morales MD, González FA, Villegas A, del Potro E, Díaz Mediavilla J, Martínez R, Alvarez A, Colomé JA.
    Sangre (Barc); 1992 Dec; 37(6):429-33. PubMed ID: 1293793
    [Abstract] [Full Text] [Related]

  • 22. Hodgkin's disease.
    Longo DL, Banks PM, Hoppe RT.
    Rev Invest Clin; 1994 Apr; Suppl():73-83. PubMed ID: 7886314
    [No Abstract] [Full Text] [Related]

  • 23. Hodgkin's disease. Treatment sequelae and quality of life.
    Henry-Amar M.
    Baillieres Clin Haematol; 1996 Sep; 9(3):595-618. PubMed ID: 8922248
    [Abstract] [Full Text] [Related]

  • 24. Late effects of cancer treatment in children.
    Ried H, Zietz H, Jaffe N.
    Pediatr Dent; 1995 Sep; 17(4):273-84. PubMed ID: 7567631
    [No Abstract] [Full Text] [Related]

  • 25. Second malignant neoplasms following childhood Hodgkin's disease: treatment and splenectomy as risk factors.
    Meadows AT, Obringer AC, Marrero O, Oberlin O, Robison L, Fossati-Bellani F, Green D, Voûte PA, Morris-Jones P, Greenberg M.
    Med Pediatr Oncol; 1989 Sep; 17(6):477-84. PubMed ID: 2586362
    [Abstract] [Full Text] [Related]

  • 26. Hodgkin's disease: complications of therapy and excess mortality.
    Hoppe RT.
    Ann Oncol; 1997 Sep; 8 Suppl 1():115-8. PubMed ID: 9187444
    [Abstract] [Full Text] [Related]

  • 27. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
    Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, Mendenhall NP, Sposto R, Chauvenet A, Schwartz CL.
    J Clin Oncol; 2007 Feb 10; 25(5):493-500. PubMed ID: 17290056
    [Abstract] [Full Text] [Related]

  • 28. [Second malignancies in patients treated for Hodgkin's disease].
    Keresztes K, Miltényi Z, András C, Illés A.
    Magy Onkol; 2002 Feb 10; 46(3):247-51. PubMed ID: 12368920
    [Abstract] [Full Text] [Related]

  • 29. The management of Hodgkin's disease.
    Rosenberg SA.
    N Engl J Med; 1978 Nov 30; 299(22):1246-7. PubMed ID: 714082
    [No Abstract] [Full Text] [Related]

  • 30. Late effects after therapy of Hodgkin's disease: update 2003/04 on overwhelming post-splenectomy infections and secondary malignancies.
    Schellong G, Riepenhausen M.
    Klin Padiatr; 2004 Nov 30; 216(6):364-9. PubMed ID: 15565552
    [Abstract] [Full Text] [Related]

  • 31. Secondary leukemia and myelodysplastic syndrome after treatment for Hodgkin's disease.
    Hoppe RT.
    Leukemia; 1992 Nov 30; 6 Suppl 4():155-7. PubMed ID: 1434819
    [No Abstract] [Full Text] [Related]

  • 32. Hodgkin's disease: treatment and secondary neoplasms.
    Kaiser HE.
    In Vivo; 1994 Nov 30; 8(5):733-6. PubMed ID: 7727720
    [Abstract] [Full Text] [Related]

  • 33. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.
    Forrest DL, Hogge DE, Nevill TJ, Nantel SH, Barnett MJ, Shepherd JD, Sutherland HJ, Toze CL, Smith CA, Lavoie JC, Song KW, Voss NJ, Gascoyne RD, Connors JM.
    J Clin Oncol; 2005 Nov 01; 23(31):7994-8002. PubMed ID: 16204014
    [Abstract] [Full Text] [Related]

  • 34. Hodgkin's disease: summary of twenty years' experience.
    Mazza P, Bocchia M, Zinzani PL, Fiacchini M, Gherlinzoni F, Bandini G, Bendandi M, Frezza GP, Neri S, Barbieri E.
    Haematologica; 1992 Nov 01; 77(6):487-93. PubMed ID: 1283856
    [Abstract] [Full Text] [Related]

  • 35. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
    Gobbi PG, Broglia C, Levis A, La Sala A, Valentino F, Chisesi T, Sacchi S, Corbella F, Cavanna L, Iannitto E, Pavone V, Molica S, Corazza GR, Federico M.
    Clin Cancer Res; 2006 Jan 15; 12(2):529-35. PubMed ID: 16428496
    [Abstract] [Full Text] [Related]

  • 36. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    Harrison CN, Gregory W, Hudson GV, Devereux S, Goldstone AH, Hancock B, Winfield D, MacMillan AK, Hoskin P, Newland AC, Milligan D, Linch DC.
    Br J Cancer; 1999 Oct 15; 81(3):476-83. PubMed ID: 10507773
    [Abstract] [Full Text] [Related]

  • 37. Treatment of paediatric Hodgkin's disease. a balance of risks.
    Thomson AB, Wallace WH.
    Eur J Cancer; 2002 Mar 15; 38(4):468-77. PubMed ID: 11872338
    [Abstract] [Full Text] [Related]

  • 38. Hodgkin's disease, splenectomy and secondary leukemia.
    Centurioni R, Brianzoni F, Leoni P, Danieli G.
    Haematologica; 1993 Mar 15; 78(4):258-9. PubMed ID: 8294062
    [No Abstract] [Full Text] [Related]

  • 39. Leukemia and other cancers after radiotherapy and chemotherapy for Hodgkin's disease.
    Boivin JF, Hutchison GB.
    J Natl Cancer Inst; 1981 Oct 15; 67(4):751-60. PubMed ID: 6944544
    [No Abstract] [Full Text] [Related]

  • 40. The late effects of childhood cancer therapy.
    Dickerman JD.
    Pediatrics; 2007 Mar 15; 119(3):554-68. PubMed ID: 17332209
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.